

119 (new). The method of claims 2, wherein the disorder is selected from the group consisting of small cell lung cancer, non-small cell lung cancer, melanoma, colon cancer, breast cancer, head and neck cancer, transitional cancer, leiomyosarcoma and synovial sarcoma.

120 (new). The method of claims 3, wherein the disorder is selected from the group consisting of small cell lung cancer, non-small cell lung cancer, melanoma, colon cancer, breast cancer, head and neck cancer, transitional cancer, leiomyosarcoma and synovial sarcoma.

C1
CONT.
SUB F3) 121 (new). The method of claim 1, wherein the nucleic acid molecule is selected from the group consisting of SOX2 (SEQ ID NO:3), SOX1 (SEQ ID NO:4), ZIC2 (SEQ ID NO:5), SOX3 (SEQ ID NO:11) and SOX21 (SEQ ID NO:12).

122 (new). The method of claim 1, wherein the nucleic acid molecule is SOX2 (SEQ ID NO:3).

SUB F4) 123 (new). The method of claim 1, wherein the nucleic acid molecule is SOX1 (SEQ ID NO:4).

124 (new). The method of claim 1, wherein the nucleic acid molecule is ZIC2 (SEQ ID NO:5).

125 (new). The method of claim 1, wherein the nucleic acid molecule is SOX3 (SEQ ID NO:11).

SUB F5) 126 (new). The method of claim 1, wherein the nucleic acid molecule is SOX21 (SEQ ID NO:12).

127 (new). The method of claim 1, wherein the biological sample is isolated from a tissue selected from the group consisting of a non-brain, non-testis, non-prostate, non-small intestine and non-colon tissue.